Synapse - Audrey Hamilton

Search Within

Audrey M Hamilton

Results (62)

Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Carter, J.; Dogan, A.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; Abramson, J. S.; Batlevi, C. L.; Joffe, E.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

Journal Article

Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
Blood Advances (2020)

Fulltext@MSK | Save

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

Journal Article

Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
Blood Advances (2020)

Fulltext@MSK | Save

Follicular lymphoma in the modern era: Survival, treatment outcomes, and identification of high-risk subgroups

Journal Article

Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Caron, P. C.; Falchi, L.; Hamilton, A.; more...
Blood Cancer Journal (2020)

Fulltext@MSK | Save

Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Meeting Abstract

Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
Blood (2019)

Fulltext@MSK | Save

High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
Blood (2019)

Fulltext@MSK | Save

A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
Blood (2019)

Fulltext@MSK | Save

A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma

Meeting Abstract

Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
Blood (2019)

Fulltext@MSK | Save

Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era

Meeting Abstract

Bobillo, S.; Joffe, E.; Seshan, V.; Noy, A.; Horwitz, S. M.; Palomba, M. L.; Matasar, M. J.; Straus, D. J.; Hamlin, P. A.; Batlevi, C. L.; more...
Blood (2019)

Fulltext@MSK | Save